Balchem Corp (BL9B.DU) Seasonal Returns Chart - Yahoo Finance
This Yahoo Finance article presents a seasonal returns chart for Balchem Corp (BL9B.DU), showing the average monthly price return from 2021 to 2026. As of November 19, the stock was trading at 150.50 EUR, down 1.57%. The article provides quick access to various financial data points for the company.
Balchem Corporation (BL9B.F) stock price, news, quote and history
This article provides a comprehensive overview of Balchem Corporation (BL9B.F) stock, including its current price, market performance, and company profile. It details the company's operations across Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products segments, highlighting its diverse product offerings and market presence. The report also includes financial statistics, earnings trends, and historical performance data for investors.
Balchem Corporation stock hits 52-week high at 183.9 USD
Balchem Corporation's stock has reached a new 52-week high of $183.9, marking a 19.94% appreciation over the past year. This milestone reflects robust performance for the specialty ingredients company, which boasts a $5.27 billion market cap and 41 consecutive years of dividend payments. Despite a slight revenue miss in Q3 2026, the company exceeded EPS forecasts and saw improved gross margins, leading H.C. Wainwright to maintain a Buy rating with a revised price target of $210.
Balchem Corporation stock hits 52-week high at 183.9 USD By Investing.com
Balchem Corporation stock reached a new 52-week high of $183.9 USD, reflecting a 19.94% appreciation over the past year. The company, a specialty ingredients firm with a market cap of $5.27 billion, reported $5.72 billion in revenue over the last twelve months and has maintained dividend payments for 41 consecutive years. Despite a slight revenue miss, Balchem exceeded Q3 2026 adjusted EPS forecasts, leading H.C. Wainwright to reaffirm a Buy rating with a revised price target.
Balchem (NASDAQ:BCPC) Looks Like a Quality Investment, but Its Valuation Is Full
Balchem (NASDAQ:BCPC) is identified as a high-quality specialty ingredients company, clearing several key quality thresholds in areas like EBIT growth, high return on invested capital (ROIC), low debt relative to free cash flow, and strong profit quality. While the company demonstrates durable compounding potential and strong financial health, its current valuation is considered full, with P/E ratios above market and industry averages, and a low valuation score. Investors are advised to consider the high valuation and verify the durability of its competitive advantages and market cyclicality.
Balchem (BCPC) Stock Looks Below Fair Value After Its 47% Run
Balchem (BCPC) stock has delivered strong returns, yet a Discounted Cash Flow (DCF) analysis suggests its current share price of US$174.60 is modestly below its intrinsic value. The company's record sales, earnings, cash generation, a new US$650m credit facility, and ongoing buybacks support future cash flow projections. Investors should consider these factors and how they align with growth, profitability, and earnings expectations to fully assess Balchem's valuation.
Five bakery trends shaping the market
The bakery market is undergoing significant changes as consumer preferences shift towards healthier, cleaner, and more convenient products. A new infographic from BakeShure® highlights key consumer trends, popular bakery formats, and strategies for optimizing products with encapsulated active ingredients to help manufacturers innovate and grow. This content is sponsored by Balchem Human Nutrition & Health.
How Strong Earnings Growth Will Impact Balchem (BCPC) Investors
Balchem Corporation reported strong third-quarter 2026 sales and net income, along with a significant share repurchase, which reduces the share count and boosts EPS. Analysts expect continued revenue and earnings growth by 2029, though some cautious perspectives exist regarding capacity utilization and market risks. The share buyback amplifies both potential benefits from new facilities and branded ingredients, as well as risks from input costs or softening pricing power.
Balchem’s CEO, CFO and investor relations director will take part in a Nov. 11 conference.
Balchem Corporation (NASDAQ: BCPC) announced its participation in Baird’s Global Industrial Conference on November 11, 2026. Chairman, President and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter will represent the company. Balchem is a global specialty ingredient manufacturer for health and nutrition markets, reporting segments in Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem 3Q 2026: Revenue $290.66M, Net income $46.73M, EPS $1.46— 10-Q Summary
Balchem (BCPC) reported strong third-quarter 2026 results, with revenue reaching $290.66 million, an 8.6% increase year-over-year. Net income rose 16% to $46.73 million, and diluted EPS increased by 17.7% to $1.46. All three reportable segments—Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products—showed sales growth, driven by various market factors and manufacturing efficiencies.
Balchem Corporation Estimates – NASDAQ:BCPC
This page on TradingView provides an overview of Balchem Corporation (NASDAQ:BCPC) financials and analyst estimates. Users can explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Balchem Reports Record Q3 Sales and Earnings, Adjusted EPS of $1.57
Balchem (BCPC) reported record third-quarter 2026 results, with net sales increasing 8.6% year-over-year to $290.7 million and net earnings rising 16.0% to $46.7 million. Adjusted diluted EPS grew to $1.57 from $1.35 in the prior year. All three business segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—contributed to sales and operating income growth.
Balchem Releases Q3 2026 Financial Results
Balchem Corporation reported Q3 2026 financial results, meeting Wall Street expectations with adjusted earnings of $1.57 per share and generating $290.7 million in revenue. The company's revenue increased 8.6% year-over-year, driven primarily by strong performance in its Human Nutrition and Health segment, which grew 8.1% to $188.2 million. Analyst sentiment for the stock remains positive, with a consensus of buy ratings.
Balchem Corp Estimates – BMV:BCPC
This page provides financial estimates for Balchem Corp (BCPC) on the Mexican Stock Exchange, allowing users to explore reported financial data and analyst estimates across various statements and metrics. It enables comparison of actual results with average, high, and low estimates, and visualization of trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.
Balchem third quarter sales rise 8.6% to $290.7 million
Balchem Corporation reported a significant increase in its third-quarter 2026 financial results, with net sales climbing 8.6% year over year to $290.7 million and GAAP net earnings rising 16% to $46.7 million. All three of its reporting segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—contributed to the sales growth. The company also saw its adjusted EBITDA increase by 12.4% to $80.3 million and demonstrated strong cash generation with $69.8 million in operating cash flow.
Press Release: Balchem Corporation Reports Third Quarter 2026 Financial Results
Balchem Corporation announced its financial results for the third quarter of 2026, reporting record net sales of $270.8 million, a 16.7% increase year-over-year. The company also achieved record GAAP net earnings of $35.4 million and adjusted net earnings of $45.1 million, reflecting strong growth across its human nutrition and health, animal nutrition and health, and specialty products segments. Balchem noted significant contributions from recent acquisitions and improved profitability.
Quarterly sales and profit set records at Balchem. Sales reached $290.7 million.
Balchem Corporation reported record financial results for the third quarter of 2026, with net sales increasing 8.6% year-over-year to $290.7 million and GAAP net earnings rising 16.0% to $46.7 million. All three reporting segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—showed growth in sales and operating earnings. The company also repurchased approximately $28 million of common stock during the quarter, reinforcing its commitment to shareholder value.
Balchem Corporation Reports Third Quarter 2026 Financial Results
Balchem Corporation reported strong financial results for its third quarter ended September 30, 2026, with record net sales of $290.7 million, net earnings of $46.7 million, and adjusted EBITDA of $80.3 million. All three reporting segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—showed healthy growth. The company also repurchased $28 million of common stock during the quarter, demonstrating a commitment to shareholder value.
Balchem Corporation (BCPC) Stock Forecasts
This page from Yahoo Finance indicates an error in retrieving data for Balchem Corporation (BCPC) stock forecasts. The content primarily consists of navigation links and market data for various indices, currencies, and commodities, suggesting a failure to load the intended article or report.
Pretax income of Balchem Corp – HAN:BL9B
This article provides financial data for Balchem Corp (BL9B) traded on the Hannover Stock Exchange, specifically focusing on its pretax income. It details the company's financial overview and notes that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet Research Systems Inc.
Non-operating income (total) of Balchem Corp – HAN:BL9B
This article provides financial data for Balchem Corp (HAN:BL9B) on the Hannover Stock Exchange, specifically focusing on its non-operating income. The data is presented in a table format showing period, value, change, and change percentage. The page emphasizes that the data is provided by ICE Data Services and FactSet.
Balchem (MEX:BCPC) Minority Interest : MXN0.00 Mil (As of Jun. 2026)
This article reports that Balchem (MEX:BCPC) has a Minority Interest of MXN0.00 Million as of June 2026. GuruFocus rates Balchem with a GF Score of 93/100, but notes two warning signs for investors to review. Minority interest represents the equity interests owned by non-controlling shareholders in consolidated financial statements.
Balchem (MEX:BCPC) Current Deferred Revenue : MXN0.00 Mil (As of Jun. 2026)
This article reports Balchem's (MEX:BCPC) Current Deferred Revenue as MXN0.00 Mil as of June 2026, according to GuruFocus. It defines deferred revenue as cash collected for revenue-producing activity not yet recognized and explains its significance. The article also provides historical data and answers frequently asked questions regarding this metric for Balchem.
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
Balchem Corporation announced a conference call for October 23, 2026, at 11:00 AM ET to discuss its third-quarter 2026 financial results. Chairman, President, and CEO Ted Harris, along with CFO Martin Bengtsson, will host the call. The company specializes in manufacturing and marketing ingredients for human and animal nutrition and health, as well as specialty chemicals.
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial ...
Balchem Corporation announced a conference call to be held on Friday, October 23, 2026, at 11:00 AM Eastern Time to discuss its third-quarter financial results. The results will be released prior to market opening on the same day. The call will be hosted by Ted Harris and Martin Bengtsson, with details provided for investors and the public to join.
Balchem Corporation Announces Quarterly Conference Call for
Balchem Corporation (NASDAQ: BCPC) announced a conference call for Friday, October 23, 2026, at 11:00 AM ET to discuss its third-quarter financial results. Chairman and CEO Ted Harris and CFO Martin Bengtsson will host the call, with results published before market opening on the same day. Investors can join via phone or webcast, with replay available online for one year.
Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026
Balchem Corporation announced a conference call for Friday, October 23, 2026, at 11:00 AM ET, to discuss its third-quarter financial results. The results will be released before the market opens on the same day. Investors and the public can join the live call or webcast, and a replay will be available for one year.
Balchem Corporation (BCPC) Stock Forecasts
This article provides stock forecasts for Balchem Corporation (BCPC), a company involved in specialty performance ingredients. Argus has raised its target price for BCPC to $167.00, with the current price at $168.63. The report offers a summary of Balchem's business and encourages users to upgrade for full access to premium research reports.
Balchem highlights the power of branded ingredients at SupplySide Global 2026
Balchem will be showcasing its branded ingredients and scientific leadership at SupplySide Global 2026, focusing on the convergence of daily performance and long-term vitality, and the demand for GLP-1 companion products. The company will present new research on ingredients like K2VITAL™, VitaCholine®, Optifolin+®, and OptiMSM®, demonstrating their benefits in cardiovascular health, cognitive function, cellular health, and athletic performance. Balchem will also feature innovative food and beverage concepts, advanced formulation solutions, and a presentation on fortification trends, alongside a new pet corner highlighting animal nutrition solutions.
Balchem Corporation (BCPC) Stock Price, News, Quote & History
This article provides a comprehensive overview of Balchem Corporation (BCPC), including its current stock price, historical data, financial performance, and analyst insights. Balchem is a specialty chemicals company operating in human nutrition, animal nutrition, and specialty products markets. The report details the company's financial metrics, earnings trends, and performance relative to the S&P 500.
Balchem: How DNA methylation supports cellular health for life
This Balchem whitepaper explores the critical role of DNA methylation in maintaining cellular health throughout life, from prenatal development to healthy aging. It delves into one-carbon metabolism, identifies nutrient gaps, and highlights the growing market for methyl-donating ingredients. The paper offers a framework for developing science-backed products that support epigenetic health across the human lifespan.
Cash flow from investing activities of Balchem Corp – HAN:BL9B
This article provides information on the cash flow from investing activities for Balchem Corp, traded on the Hannover Stock Exchange under the symbol BL9B. It appears to be a financial data point from TradingView, indicating that the market is currently closed with no trades. The content primarily lists various navigation and informational links related to the TradingView platform.
Cash flow from operating activities of Balchem Corp – HAN:BL9B
This page provides financial data for Balchem Corp (HAN:BL9B) on the Hannover Stock Exchange, specifically focusing on its cash flow from operating activities. It indicates that the market is currently closed with no trades recorded. The data is supplied by ICE Data Services and FactSet.
Balchem Corp Revenue Breakdown – HAN:BL9B
Balchem Corp's financial data for the last year shows a total revenue of 883.06 M EUR. The Human Nutrition and Health segment was the top performer, contributing 561.41 M EUR. The United States was the primary regional contributor, accounting for 646.61 M EUR of the revenue.
Net income before discontinued operations of Balchem Corp – HAN:BL9B
This article presents the net income before discontinued operations for Balchem Corp, traded on the Hannover Stock Exchange under the symbol BL9B. It shows a table with the period, value, and change for this financial metric. The content is primarily a financial data point rather than a descriptive analysis.
Most of the shares held directly by Balchem's (BCPC) R&D chief are restricted and vest over time.
Balchem's SVP and Chief R&D Officer, Ren Anthony Gonzalez, reported holdings including 6,335 directly held common shares and 884 indirectly held common shares in a 401(k) Plan as of September 16, 2026. A significant portion of his direct holdings, 6,133 shares, are restricted stock that vests over one to three years. Gonzalez also holds an employee option for 240 common shares with an exercise price of $143.43, exercisable from February 8, 2027.
Balchem Corporation (BCPC) Stock forecasts
Argus has raised its target price for Balchem Corporation (BCPC) to $185.00, up from its current price of $167.84. Balchem Corp specializes in developing, manufacturing, and marketing specialty performance ingredients for various industries. The report was published on September 23, 2026.
Balchem (BCPC) Stock Could Be 25% Undervalued On Cash Flow
Balchem's stock has returned 38.7% over the past three years, prompting a focus on its current valuation against cash flows. A Discounted Cash Flow (DCF) analysis suggests Balchem, with a last twelve-month free cash flow of $177.6m and projected growth, is currently undervalued by about 25% compared to its intrinsic value. While a bull case highlights capacity expansion, a bear case suggests potential risks of underutilized capacity.
Balchem study shows Optifolin+ boosts DNA methylation, boosting link to healthy ageing
A new study led by the University of Arkansas and announced by Balchem found that Optifolin+ significantly enhances cellular methylation capacity and DNA methylation in a human cell model. This research, published in the Journal of Dietary Supplements, provides mechanistic evidence for the choline-enriched L-5-MTHF ingredient's epigenetic activity, strengthening its potential for healthy aging and one-carbon metabolism formulations. The findings highlight Optifolin+'s role in epigenetic regulation by increasing S-adenosylmethionine (SAM) by 71% and enhancing cellular DNA methylation by up to 14 times.
Balchem Corporation to Participate in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026
Balchem Corporation announced its participation in the 9th Annual Wells Fargo Consumer Conference on September 23, 2026. Key executives, including Chairman and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director Investor Relations Allison Baurichter, will represent the company. Balchem specializes in developing and manufacturing specialty ingredients for health and nutrition markets, across human nutrition, animal nutrition, and specialty products segments.
Balchem Corp Revenue Breakdown – BMV:BCPC
Balchem Corp (BMV:BCPC) generated 18.70 billion MXN in revenue last year, with its Human Nutrition and Health segment contributing the most at 11.89 billion MXN. The United States was the largest regional contributor, accounting for 13.69 billion MXN of the company's revenue.
Top tips for keeping up with the protein boom
This article highlights the growing consumer demand for protein, particularly in meat snack sticks, and offers strategies for manufacturers to keep pace. It encourages downloading an infographic from Balchem that explores market drivers, new opportunities from GLP-1 use and better-for-you snacking, and product development strategies. The infographic also details how Balchem’s MeatShure® microencapsulated acids can boost production capacity.
Balchem (BCPC) Q2 Results Raise The Question Of Whether The Stock Is Fully Valued
Balchem (BCPC) recently reported strong Q2 2026 results with higher sales, net income, and EPS, leading to share price momentum. While one valuation narrative suggests the stock is 14.4% undervalued with a fair value of $207, driven by growth in its microencapsulation facility and improved margins, another view highlights potential overvaluation. The company's P/E ratio of 34.3x is higher than the US Chemicals industry (29.4x) and peers (25.7x), indicating valuation risk if sentiment cools.
Did Balchem’s Strong Q2 Results and Completed Buyback Just Shift Balchem's (BCPC) Investment Narrative?
Balchem Corporation (BCPC) reported strong Q2 2026 results with higher sales and net income, alongside completing a share repurchase program worth US$55.49 million. These actions suggest management confidence and improve the company's earnings per share, impacting its investment narrative. While the results are encouraging, investors should still consider risks related to product innovation and tariff exposure.
Balchem Corp (BCPC) Stock News Today
This article provides current news and financial data for Balchem Corp (BCPC), a chemicals company. It highlights recent earnings, specifically Q2 2026 results where all three segments drove an 11.2% sales growth. The page also offers stock performance, analyst ratings, and other key developments for investors.
Balchem (BCPC) Could Be 16% Undervalued As Q2 Results And Buybacks Land
Balchem (BCPC) recently released its Q2 2026 results and provided an update on its share buyback program. The stock is considered 16% undervalued, with a fair value estimated at $207 compared to its current price of $174.78, driven by its new microencapsulation facility and projected sales growth. However, its P/E ratio of 33.9x compared to an industry average of 25x suggests potential valuation risk if market sentiment shifts.
H.C. Wainwright raises Balchem stock price target on strong earnings
H.C. Wainwright has increased its price target for Balchem (NASDAQ:BCPC) to $215 from $190, reiterating a Buy rating, following the company's strong second-quarter 2026 financial results. Balchem reported revenue of $284 million, exceeding estimates, and GAAP net earnings of $1.39 per diluted share, also surpassing forecasts. The firm raised its full-year 2026 revenue and earnings projections, citing Balchem's consistent growth, healthy gross profit margin, and 16 consecutive years of dividend increases.
Balchem (BCPC) Stock Gains Look Muted Next To Record Margins
Balchem (BCPC) reported record quarterly revenue and adjusted earnings, yet its stock only saw a 3% gain. The company's net profit margin is up, and it achieved record adjusted EBITDA, indicating strong profitability trends. Despite a high 34.1x P/E ratio, the earnings quality suggests that the stock's current valuation needs to be further evaluated against its financial health and future growth prospects.
Balchem Corporation Revenue Breakdown – NASDAQ:BCPC
Balchem Corporation (BCPC) generated $1.04 billion USD in revenue last year, with its Human Nutrition and Health segment being the top performer at $659.39 million USD. The United States was the largest contributor to revenue, accounting for $759.45 million USD. These figures highlight the company's key revenue streams and geographic strength.
Q2 2026 Balchem Corp Earnings Call Transcript
Balchem Corp reported record consolidated sales of $284 million, up 11.2% year-over-year, and record adjusted EBITDA of $78 million for Q2 2026. The growth was broad-based across all segments, including significant gains in Animal Nutrition & Health and Specialty Products, while Human Nutrition & Health also saw record sales. Despite higher input costs and operating expenses, the company demonstrated consistent performance with its 28th consecutive quarter of year-over-year growth in adjusted EBITDA and strengthened its financial flexibility through a revolving credit facility refinancing.